Bayer's stocks have seen a rollercoaster ride with a slump to a 20-year low primarily due to a bleak 2025 earnings forecast and a disappointing Q3 performance report, despite sales being boosted by Nubeqa and Kerendia. This downturn generated a call from shareholders for more rapid changes. Their shares also took a hit due to a U.S. court's decision to review the Monsanto Case and reopen the PCB issue. A consequent lowering of outlook only amplified the fall. But amid the storm, Bayer witnessed a soar of 11%, following a key U.S. legal win against Roundup cancer claims. Another contributing factor to Bayer's slump is its weak performing agricultural unit, compelling the company to cut its operating earnings outlooks. Despite these setbacks, Bayer is taking steps to tackle the debt burden by cutting its dividend. Nevertheless, key legal victories, potential for restructuring and advancements in drug trials suggest potential upside for Bayer.
BAYER Stocks News Analytics from Thu, 18 Jan 2024 08:00:00 GMT to Sat, 16 Nov 2024 05:12:28 GMT -
Rating -5
- Innovation -4
- Information 8
- Rumor -4
